Please enable JavaScript.
Coggle requires JavaScript to display documents.
Prescription Opioid Abuse in the US (Potential Solutions Intended to…
Prescription Opioid Abuse in the US
Factors Contributing to the severity of the problem
Role of Pharmaceutical Industry
Role of Physicians
Correlation/Causation between availability of drug & abuse
Social acceptability of using medications for different purposes
Public is not well-informed
"Environmental Availability" of drugs due to: 1) increase in number of prescriptions, 2) social acceptability, 3)aggressive marketing by pharmaceutical companies
Drastic increases in the number of prescriptions written & dispensed
Potential Solutions Intended to Mitigate Abuse [must be evidence-based & data-driven]
Advancements in Science-- Deterrent based formulas for medications
Laws/Regulations: Federal, State, and Local levels [no organization or agency can address the problem alone; coordinated response is required]
Expansion of/Requirement to use the Prescription Monitoring Database
Successfully implemented frameworks to emulate
"Real-time" data: providing the ability to become aware of a problem before it become a full blown crisis
Improved education for patients & healthcare providers [physicians, pharmacists, etc.]
Development of a more convenient & environmentally responsible disposal method to remove unused medication from the home
Reduce prevalence of pill mills & doctor shopping through targeted enforcement efforts
"Multi-pronged strategy that minimizes the intrinsic risks of opioid medications & make effective, long-term treatments available
Why does this public health crisis need to be addressed?
Social Responsibility: Ethical/Moral Obligation
Economic burden on society
Negative Fiscal Impact
Increase in number of overdose-related deaths
Health, social, & economic welfare of the country
Who is affected?
Geographical region
Socioeconomic Class
Race, Age, Gender, Sex
Case Analysis: Purdue & OxyContin
Aggressive Marketing Techniques
Misrepresentation of Addictive Components
Doctor Profiling
Financial Incentives to Sales Representatives
Regulatory Oversight
FDA
Asymmetric Information
Regulatory Oversight